Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults

Inclusion Criteria: * Age 18 to 49, inclusive at the time of enrolment * in good health as determined by the outcome of medical history, physical examination screening/baseline labs and clinical judgment of the investigator * Male * Must have received polio vaccinations with OPV according to the Polish National Immunization Program as a child based on vaccination cards or information given by subjects during interview with investigator * Preferred: number (and date) of polio vaccinations known * Willingness and ability to adhere to the study regimen * Having a signed informed consent form Exclusion Criteria: * IPV or OPV booster dose after the age of 12 years * Positive for HIV, Hepatitis B or Hepatitis C * Known or suspected allergy against any of the vaccine components * History of unusual or severe reactions to any previous vaccination * Known or suspected disease or use of medication that may influence the immune system * Known or suspected immune deficiency * Systemic treatment with corticosteroids within one month before screening * Administration of plasma (including immunoglobulins) or blood products three months prior to the study * Blood donation within one month before screening * Any vaccination within three months before screening and during the study until the last visit * History of any neurological disorder including epilepsy or febrile seizures * Evidence of excessive alcohol use or drug use * Any infectious disease at the time of screening and/or inclusion * Participation in another clinical trial within three months before screening * Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator * Bleeding disorders or the usage of anticoagulants